In a cohort of 440 PAD patients, a 100 μg/L increase in baseline IGFBP-2 levels was significantly associated with a higher risk of cardiovascular mortality (adjusted HR 1.12, 95% CI: 1.01–1.24). Here, IGFBP2 is linked to peripheral arterial disease.